Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
For more information, visit www.wsgr.com.
Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO, and nanotech have been located in BioBAY. 8000 scientists and professionals have come to join this dynamic innovative community, including 60 talents of The Recruitment Program of Global Experts.
BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:
- Cold Spring Harbor Asia Conference Centre — cutting-edge academic resources and global technical communication
- BioTOP — one-stop professional solutions for biomedical companies, including analysis & test, GMP verification, biomaterials trading, training, etc.
- BioBAY Sangtian Island — commercialization base for high-tech drug, medical device and IVD companies
- BioBAY Changshu — top class industrial base for biomedical industry with international advanced standards
Eight Roads Ventures is a global venture capital firm that backs entrepreneurs with aspirations for greatness. It has over 20 years of venture capital experience in China and has supported over 80 companies in the country’s healthcare, enterprise technology and consumer technology sectors. As the proprietary investment arm of Fidelity International Limited, Eight Roads is committed to building bold and meaningful businesses and together with its associated funds manages USD 3.6bn of capital across offices in the China, Japan, UK, India and the US.
Eight Roads Ventures led successful investments in China, including Alibaba, China PnR, Wuxi PharmaTech, Hile, Innovent, Adagene and Hua Medicine. It launched its first USD 250 m China Healthcare Fund in 2017. eightroads.com
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OAP has made PE investments in 29 companies, with close to USD$500 million under management. OrbiMed has also invested over USD$1 billion in the stocks of Asia public healthcare companies. For More information, please vist www.orbimed.com.
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers. www.pharmadj.com
Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 400 licensing and acquisition opportunities and raise over USD 500 million in funding in China.
The 2018 BioCentury China Healthcare Summit is an annual forum to identify the essential next steps to creating a modern healthcare ecosystem in China based on a foundation of scientific, business and policy innovations. This VIP event is organized by BioCentury and BayHelix in collaboration with McKinsey & Co. It is a closed-door meeting limited to senior-level biopharma and medtech executives, investors and academia. The Summit features two days of action-oriented discussion and networking among peers. Attendees will receive an exclusive conference report from McKinsey documenting market trends and identifying business imperatives for China healthcare innovators. For more information, please contact Joshua Berlin at firstname.lastname@example.org or WeChat ID: "joshberlin", or visit our website: www.BioCenturyChinaSummit.com.
BioCentury is the essential source of intelligence for a global audience of biotech and pharmaceutical company professionals, investors, researchers, service providers and industry stakeholders who demand deep industry knowledge, data-driven analysis, independent perspective and a commitment to accuracy. Our insight, trusted reporting and in-depth analysis are built on independent, objective surveillance of the biotechnology sector, producing the industry's most respected journals and data solution resources, since 1993. For more information please visit:www.biocentury.com
Founded in 2002, GBI (www.gbihealth.com) is an information, applications and services company focused on the healthcare industry. It boasts a diverse portfolio of marketing intelligence solutions that enable organizations and individuals to make data-driven decisions and communicate more effectively. Over 15 years of development, GBI has built a global presence with around 200 staff across four locations in Shanghai, Beijing, São Paolo, and Washington, DC. Our first database product was launched in 2009, and we have now built a portfolio based around the flagship brands of SOURCE, DEVINT, METRIX and NAVIS, covering the markets of China, Latin America, and the United States. GBI is now a trusted provider for the pharmaceutical and medtech industries, with established long-term partnerships with multinational industry players. www.gbihealth.com